Compassionate Use Individual Request Program for GSK525762 in NUT Midline Carcinoma
- Conditions
- Solid Tumours
- Registration Number
- NCT03702036
- Lead Sponsor
- GlaxoSmithKline
- Brief Summary
Compassionate use access to molibresib/GSK525762 for eligible participant with NUT Midline Carcinoma; indication is a seriously debilitating or life-threatening disease.
- Detailed Description
Investigational Product GSK525762 is an orally bioavailable small molecule that is a potent inhibitor of the binding of BET proteins to acetylated histones. Binding of GSK525762 induces squamous differentiation and inhibits proliferation of patient-derived NMC cell lines both in culture and in murine xenografts.
Compassionate use access to molibresib is restricted to patients with confirmed diagnosis of NUT Midline Carcinoma.
Recruitment & Eligibility
- Status
- NO_LONGER_AVAILABLE
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Read More
Exclusion Criteria
Not provided
Read More
Study & Design
- Study Type
- EXPANDED_ACCESS
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method